Work

Mutant KRAS vaccination for pancreatic cancer interception: the G12D immunogenicity paradox

Year: 2026

Type: article

Abstract: In a recent study published in Cancer Discovery , Haldar and colleagues report the first-in-human evaluation of a pooled mutant (Kirsten rat sarcoma viral oncogene homolog) KRAS peptide vaccine in individuals at high risk of pancreatic ductal adenocarcinoma (PDAC). Vaccination induced broad and durable mutant KRAS-specific T-cell responses in most participants, providing a proof of concept for targeting oncogenic driver mutations before invasive pancreatic cancer develops. 1

Source: Signal Transduction and Targeted Therapy

DOI: 10.1038/s41392-026-03088-3

Authors: Morten Orebo Holmström, Mie Linder Hübbe, Inna Markovna Chen, Mads Hald Andersen

Institutions: University of Copenhagen, Herlev Hospital, Copenhagen University Hospital

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,790